GLP-1 receptor agonist
Semaglutide
Also known as Ozempic, Wegovy, Rybelsus.
Stage Approved
Indications Type 2 Diabetes, Obesity, Cardiovascular Risk
Last updated:Jul 15, 2026Source:ClinicalTrials.gov + sponsor pipeline pagesVerified:Manually reviewedData provider:PeptidePlanet Research
Mechanism
Long-acting GLP-1 analog improving glycemic control and reducing appetite.
Educational summary. Not medical advice. See sponsor materials and peer-reviewed literature for full pharmacology.
Companies developing it
1Related trials
2Current research
Data unavailableCurated peer-reviewed research links launch once our editorial pipeline is verified.
Safety summary
Data unavailableSafety summaries require a verified regulatory data source and clinical review. Consult the FDA label and sponsor prescribing information for approved products.